Pat Garcia-Gonzalez: A Bold Plan to Double Impact and Reach 100,000 Patients by 2031
Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared a post on LinkedIn:
”I am excited to invite you to our 2026 State of the Organization, a virtual presentation where I’ll share our vision and priorities at The Max Foundation.
In the year ahead, we are deepening our commitment to what matters most: developing a strategy to more than double our impact by reaching 100,000 patients annually by 2031. This is the driving force behind every partnership we build and every innovation we pursue.
During the presentation, I’ll discuss four organizational priorities for the year and what they mean in real world practice. In 2026, we’re building on that foundation and reaching farther than ever before.
I hope you’ll join me to hear more about how, together, we can continue advancing health equity around the world.
Date: February 19, 2026, 8:00 AM PT
Let’s make this a year of bold impact—one patient, one partnership, one breakthrough at a time.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 13:42New EAS Consensus Highlights Advances in Pediatric FH Care
-
May 27, 2026, 13:10Amos Gitonga Mbaabu: Global Partnerships Supporting Hemophilia and Sickle Cell Care in Africa
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism